PRNewswire

TORONTO, Nov. 20, 2024 /PRNewswire/ — AmacaThera today announced results from its Phase 1 clinical trial of AMT-143, an innovative, non-opioid anesthetic, formulated with the company’s patented AmacaGel™ platform, demonstrating sustained anesthetic release out to 14 days. AMT-143 is in

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: